Hepatitis D Market – Opportunities, Share, Growth and Competitive Analysis and Forecast 2029
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Projected Valuation Of The Hepatitis D Market In The Coming Years?
In the last few years, the hepatitis D market size has been expanding consistently. Projected growth will see it increase from $0.72 billion in 2024 to $0.76 billion in 2025, boasting a CAGR of 4.3%. A limited range of treatment options, a high incidence in endemic areas, concurrent infection with hepatitis B, below-par awareness and diagnosis rates, as well as state-run vaccination drives, have all contributed to the buoyant development during the historic period.
The hepatitis d market is anticipated to witness a consistent growth trajectory in the coming years, reaching a value of $0.89 billion in 2029 with a CAGR of 4.2%. This growth during the projected period can be associated with broadening reimbursement policies regarding innovative therapies, escalated investments in the healthcare domain, increased usage of combination treatments, expanding hepatitis B vaccination coverages, and burgeoning public health campaigns. Key trends expected during this period include the advancement in molecular diagnostic technologies, a shift towards personalized medicine for treating liver diseases, evolution of new RNA-based therapies, the broadening of clinical trials concerning hepatitis D treatments, and the implementation of telemedicine for managing hepatitis.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21202&type=smp
What Drivers Are Accelerating Expansion Of The Hepatitis D Market?
The projected expansion of the hepatitis D market is directly linked to the rising incidences of hepatitis B. This viral infection targets the liver, resulting in symptoms such as fatigue, jaundice, and abdominal distress, potentially escalating to chronic liver disease or liver cancer if not appropriately managed. The surge in Hepatitis B instances is due to reasons including unsafe sexual practices, needle sharing, transmissions from mother to child during birth, and insufficient vaccination in some areas. Hepatitis D relies on the Hepatitis B virus surface antigen to infect liver cells, making this co-infection crucial for liver disease progression. For instance, in November 2023, the Department of Health and Human Services, a US government department, revealed that chronic hepatitis B cases newly reported in 2022 experienced an 11% increase compared to 2021. This highlights how the escalating prevalence of hepatitis B fuels the expansion of the hepatitis D market.
How Is The Global Hepatitis D Market Broken Down By Segment?
The hepatitis dmarket covered in this report is segmented –
1) By Type: Acute; Chronic
2) By Diagnosis: Blood Tests; Elastography; Liver Biopsy; Serologic Testing; Other Diagnosis
3) By Distribution Channel: Hospital pharmacies; Retail pharmacies; Online Pharmacies
4) By End-Users: Clinic; Hospital; Other End Users
Subsegments:
1) By Acute: Self-limiting Acute Hepatitis D; Severe Acute Hepatitis D
2) By Chronic: Compensated Chronic Hepatitis D; Decompensated Chronic Hepatitis D
Which Market Trends Are Expected To Define The Future Of The Hepatitis D Market?
Major companies in the hepatitis D market are concentrating on launching innovative solutions like recombinant vaccines to improve the effectiveness of immunization and offer durable protection against the virus. Recombinant vaccines are created by inserting a gene that encodes a viral protein into a host organism, such as yeast or bacteria, which then produces the protein used to trigger an immune response without causing the disease. For example, in December 2022, VBI Vaccines Inc., a US-based biotechnology firm, secured approval from Health Canada for PreHevbrio [3-antigen Hepatitis B Vaccine (Recombinant)], which is intended for the active immunization of adults aged 18 and above against all recognized subtypes of hepatitis B. Since hepatitis D is dependent on hepatitis B infection, this approval also helps in preventing hepatitis D. The decision was based on favorable results from two key Phase 3 trials, Protect and Constant, which showed that PreHevbrio achieved higher seroprotection rates compared to the single-antigen Engerix-B vaccine.
Which Firms Are Making The Biggest Impact In The Hepatitis D Market?
Major companies operating in the hepatitis d market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Viatris Inc, VBI Vaccines Inc, Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dynavax Technologies Corporation, Echosens S.A, Arbutus Biopharma Corporation, PROBIOMED SA de CV, Assembly Biosciences Inc., Replicor Inc., Eiger BioPharmaceuticals Inc, Bluejay Therapeutics Inc, Janssen Pharmaceuticals Inc., Transgene SA, Vir Biotechnology Inc, Biorex Diagnostics Ltd.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/hepatitis-d-global-market-report
Which Geographic Regions Are Creating Strong Demand In The Hepatitis D Market?
North America was the largest region in the hepatitis D market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis d market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=21202&type=smp
Browse Through More Reports Similar to the Global Hepatitis D Market 2025, By The Business Research Company
Hepatitis Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hepatitis-drugs-global-market-report
Non Alcoholic Steatohepatitis Treatment Global Market Report 2025
Non Alcoholic Steatohepatitis Nash Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
